Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) Revenue: ₽139.4 Mil (TTM As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIC:GEMA Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC MIC:GEMA
17 GF Score
Price ₽101.40
View Full Analysis

What is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Revenue?

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC MIC:GEMA -5.67% 17 Revenue is ₽139.4 Mil as of Dec. 2023. GuruFocus rates MIC:GEMA with a GF Score™ of 17/100.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's revenue for the three months ended in Dec. 2023 was ₽70.1 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₽139.4 Mil. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Revenue per Share for the three months ended in Dec. 2023 was ₽4.70. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₽9.33.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC  (MIC:GEMA) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Revenue Related Terms


Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Revenue Historical Data

* Premium members only.

The historical data trend for Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Revenue Chart

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 238.59 242.63 265.89 254.68 283.51

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.94 62.20 69.23 0.00 70.13

MIC:GEMA vs FICO, SPSC, RDVT: Revenue Comparison

For the Medical Care Facilities subindustry, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Revenue vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Revenue distribution charts can be found below:

* The bar in red indicates where Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Revenue falls into.


MIC:GEMA
17GF Score
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC MIC:GEMA
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₽139.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of ₽139.4 Mil mean?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) has a Revenue of ₽139.4 Mil as of Dec. 2023. Revenue is the total amount a company generates as sales through its operations. View historical data on Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC and its competitors.
Is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Revenue too high?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current Revenue is ₽139.4 Mil. Overall, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Revenue compare to FICO and SPSC?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's Revenue of ₽139.4 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC and its competitors. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current Revenue is ₽139.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC stock overvalued right now?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) has a current Revenue of ₽139.4 Mil. The current Revenue is ₽139.4 Mil. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA), the current Revenue is ₽139.4 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Business Description

Address Ulitsa Gubkina, d. 3, Building 1, Floor 1, Moscow, RUS, 119333
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC, through its subsidiary, is engaged in offering personal storage of cord blood stem cells in Russia and Eastern Europe. The services provided by the company include Cord Blood Cell Preservation, Program for the treatment of Cerebral Palsy, Cord Blood DNA isolation, and Umbilical Cord tissue, among others.
17GF Score

Get the complete analysis for MIC:GEMA

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽101.40
Price